Found 35 matching trials
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
PHASE1This is a randomized, open, comparative, multi-centre study which will recr...
Location
Institut Ste Catherine
......SMARTEST Trial......
PHASE2The SMARTEST trial is a phase II non-blinded randomized trial designed to e...
Location
Princess Margaret Cancer Centre
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
PHASE2Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of chol...
Location
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
PHASE1In over 60% of cases, squamous cell carcinoma of the head and neck (SCCHN) ...
Location
Multiple Locations
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
PHASE2This is a phase II trial of adjuvant chemotherapy and immunotherapy for com...
Location
University of Illinois Chicago
Microbiome Immunotherapy Toxicity and Response Evaluation
N/AThis is a observational study to investigate how the microbiome correlates ...
Location
Royal United Hospitals Bath NHS Foundation Trust
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure
PHASE2This project is a Phase 2 trial testing the safety and efficacy of treatmen...
Status
Active Not Recruiting
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma
PHASE1Chemotherapy is controversial for soft tissue sarcoma that has not yet meta...
Location
University of Arizona
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
PHASE3This phase III trial compares the effect of adding AZD6738 to durvalumab ve...
Status
Active Not Recruiting
Location
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Durvalumab and Tremelimumab in Resectable HCC
PHASE2Hepatocellular Carcinoma (HCC) is the third most common cause of death from...
Location
University Health Network